Featuring an interview with Dr Jennifer Crombie, including the following topics:

• Overview of similarities and differences among CD20 x CD3 targeted bispecific antibodies for the treatment of lymphomas (0:00)
• Optimal integration of CD20 x CD3 bispecific antibodies into treatment algorithms for lymphomas (9:40)
• Case: A man in his late 60s with relapsed follicular lymphoma (FL) who received mosunetuzumab (23:52)
• Case: A man in his late 80s with transformed, double-hit diffuse large B-cell lymphoma (DLBCL) who received epcoritamab (28:46)
• Case: A woman in her early 70s with recurrent FL who received odronextamab on the ELM-1 trial (34:06)
• Case: A man in his early 80s with multiregimen-relapsed DLBCL who receives glofitamab (43:19)

CME information and select publications

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

• Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00)
  • Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract
  • Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01.
• Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00)
  • Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract
• Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25)
  • Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract
• Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57)
  • Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5.

CME information and select publications

Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics:

• Introduction (0:00)
• Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04)
• First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation — Dr Liu (26:59)

CME information and select publications